Is Thymosin Alpha-1 Legal in Pennsylvania? How to Access It Legally

HealthRX.com

Thymosin alpha-1 is not FDA-approved and has no US route

Print or save as PDF

Key numbers

  • 1.6 mgItalian Zadaxin label dose of thymosin alpha-1 (no US-approved dose exists)Source: fda.gov, as cited Nov 7, 2026
  • 45.8%HBeAg loss at 72 weeks with thymosin alpha-1 plus interferon in a double-blind trial, not statistically significantSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 4,400 peoplePeople enrolled in Zadaxin trials, per authors tied to the manufacturer (company-linked data)Source: fda.gov, as cited Nov 7, 2026
  • FDA approval / Not approved in the US; four orphan drug designations only [1]
  • FDA list, state-licensed pharmacies / In none of the three categories [2]
  • FDA list, outsourcing facilities / Category 3, nominated without adequate support [3]
  • Advisory committee vote / 4 yes, 17 no, December 4, 2024 [4]
  • Approved abroad / Italy, India and Hong Kong, for specific uses [1]
  • Pennsylvania law / Not covered on this page

Is thymosin alpha-1 FDA-approved?

No. A Drugs@FDA search found no US application for it, and FDA's December 2024 review notes four US orphan drug designations, which are a separate process from approval [1].

It is approved as a medicine in some other countries. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1]. Two reviews by authors tied to the Zadaxin developer put the figure at over 35 countries in 2009 and more than 30 countries in 2007 [5][6].

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymosin fraction 5 [1]. It is described as an immune modulator that augments T-cell function [7]. Zadaxin is the brand of finished 1.6 mg injection sold outside the US and is not interchangeable with bulk peptide powder [1].

What do FDA's compounding lists say?

Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach patients [8].

Thymosin alpha-1 was in category 2, FDA's list of bulk substances that may present significant safety risks, and now appears in the nominated-but-withdrawn table because the nominators withdrew it [9]. FDA's listed concerns remain: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [9].

It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, and FDA's category 1 policy of generally not acting against compounders does not apply to it [2]. On the outsourcing facility list, updated March 21, 2025, it is in category 3, nominated without adequate support [3]. On December 4, 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4].

Does a prescription create a route to it?

FDA describes a valid patient-specific prescription as one condition of compounding by state-licensed pharmacies, and says outsourcing facilities may also fill orders that are not for an identified patient [8]. Thymosin alpha-1 is in none of the pharmacy list categories and in category 3 on the outsourcing list [2][3].

Questions worth asking

Choose the questions you want to keep

What do the trials show?

A 2026 Cochrane review of randomized trials in chronic hepatitis B concluded that the reviewers were not sure thymosin alpha-1 helps [10]. In a double-blind trial, 98 adults received 24 weeks of lymphoblastoid interferon plus thymosin alpha-1 (n=48) or placebo (n=50); loss of HBeAg at 72 weeks was 45.8% versus 28.0%, a difference of 17.8% (95% CI -1.2 to 35.3, P=0.067), which did not reach statistical significance [11].

What is known about safety?

FDA's search of its adverse-event database in April 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and over 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild; that is company-linked data [1].

There is no US-approved dose [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination, and says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What does the article say about the four US orphan drug designations for thymosin alpha-1?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is thymosin alpha-1 legal in Pennsylvania?
This page covers federal status only. FDA shows the peptide is not approved in the US [1], is in none of the three categories on the bulk substance list for state-licensed pharmacies and physicians [2], and is in category 3 for outsourcing facilities [3]. Pennsylvania law is not addressed here.
Can a pharmacy compound thymosin alpha-1?
FDA proposed that it not be added to the pharmacy bulks list, and its Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on December 4, 2024 [4]. FDA's category 1 policy of generally not acting against compounders does not apply to it [2].
Where is thymosin alpha-1 approved?
Italy, as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. It has no US approval, and four orphan drug designations are not approvals [1].
Does thymosin alpha-1 work?
A 2026 Cochrane review of randomized trials in chronic hepatitis B concluded that the reviewers were not sure thymosin alpha-1 helps [10].
Show all 11 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. U.S. Food and Drug Administration.
  5. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  6. Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
  7. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  8. Human Drug Compounding Laws | FDA.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
  11. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
Evidence overview for Is Thymosin Alpha-1 Legal in Pennsylvania? How to Access It Legally